Lisa M. Dunkle, MD

Vice President, Global Medical Lead
Novavax, Inc.

Disclosure(s): Novavax, Inc.: contractor for Novavax, Stocks/Bonds (Public Company)

Poster(s):

• (P-1655) Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform–Specific Priming and Immune Imprinting
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET

• (P-1657) Difference in reactogenicity events between mRNA and Protein-subunit Vaccines: Results from the Booster Epidemiological Evaluation of Health, Illness, and Vaccine Efficacy (BEEHIVE) Study, a U.S. randomized trial of 2023-2024 COVID-19 vaccines (XBB.1.5)
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET